For research use only. Not for therapeutic Use.
KUS121 is an ATPase inhibitor of valosin-containing protein (VCP) with an IC50 value of 330 nM; Neuroprotectant.
KEYWORDS: KUS121 | suppler | VCP inhibitor | KUS 121 | KUS-121 | CAS [1357164-52-3] | [1357245-09-0] | ATP | ATPase (p97) | Inhibitor | Enzymes | Non-arteritic central retinal artery occlusion | Ischemic stroke | Retinitis pigmentosa
| Catalog Number | I030204 |
| CAS Number | 1357164-52-3 |
| Molecular Formula | C22H16FN4NaO3S |
| Purity | ≥95% |
| IUPAC Name | sodium;4-amino-3-[[6-(4-fluoro-2-methylphenyl)pyridin-3-yl]diazenyl]naphthalene-1-sulfonate |
| InChI | InChI=1S/C22H17FN4O3S.Na/c1-13-10-14(23)6-8-16(13)19-9-7-15(12-25-19)26-27-20-11-21(31(28,29)30)17-4-2-3-5-18(17)22(20)24;/h2-12H,24H2,1H3,(H,28,29,30);/q;+1/p-1 |
| SMILES | CC1=C(C=CC(=C1)F)C2=NC=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])N.[Na+] |
| Reference | H Kinoshita et al. KUS121, a valosin-containing protein modulator, attenuates ischemic stroke via preventing ATP depletion. Sci Rep. 2019;9(1):11519. HO Ikeda et al. Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS One. 2020;15(2):e0229068. HO Ikeda et al. Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa. Sci Rep. 2014;4:5970. |
